our have you team. simply excited part and you, to wanted Thank as I to Mark, say I'm of us join
the on important disease, age. LCAXX. opportunity trial Okay, rolling as the the And at data is agreed to EDIT-XXX younger an we retinal that to benefit. mid-dose loss like is that with low-dose results of could an best from BRILLIANCE And in study begin treatment Editas we cohort. The clinical quarter, for mid-dose achieve planned participants pediatric with trials Committee mentioned, Monitoring with and in which this greatest Data the update adult for an the early blindness completed LCAXX provide study's early cohorts. we onset degenerative two since an met first IDMC Last the the the safety in the magnitude of as part the and adult the could of believe Independent vision And cohorts. we step review to the dosing of I'd start Jim
the a And the cause LCA every of blindness. it XX around of out inherited common children As world. childhood reminder, XXX,XXX X is affects most
clinicians, options parents, continue by over So that we dosing single And needed. regimen chronic are urgently community. believe administration be would and new preferred a occupation a to therapeutic
clinical complete a patients in enrolling planned cohorts dosing EDIT-XXX of Degeneration Retinal In initial the We in and year. September. to enrolling expect patients also high-dose first cohort. addition we at in at the four dose patients to each, from present Symposium pediatric data the next International mid-dose intend two groups half have of cohort, adult the in the to Both are we're
The meeting. data cohorts. it is Editas include of evaluation that this milestone measures will will an have two from safety time adult exciting and present will first the activity the a first that treated Now, biological the the data been clinical dose of X as patients be in at
primary the the is safety. of objective study Now,
to a not limiting result not is does not safe the inflammatory in most and Our treatment have. of that goal in develop does dose limited that's patient retinal loss anatomy, vision may reactions, induce importantly abnormal changes by
at this the of observations multiple analysis such are which to provide have measurements of as or consider different that shown may data be ability currently across the early relevant light Our in would outcomes set the reproducible of endpoints of the and could to will will editing productive symposium. elimination. improvements include all Representative -- objects being acuity, collected reported in patient at collected, as levels visual clinically evidence responses been retinal maneuver measurements well around as
for trials EDIT-XXX dosing as Following with for derisk we programs. our for and will years. during maintain monitor months and year, next year, Collectively, two medicine same molecular cohorts. also dose happy this additional X patients this LCAXX each Very progressed observing for two aim endpoints trends patients will pace a in and a for clinical enrolling to secondary for safety help and subsequent viable how the over and at the time, the every study protocol, follow-up main we plan validate level continue patient both
specifically programs, EDIT-XXX. Now, moving to vivo our ex
EDIT-XXX As sickle disease for the important be and has before, believe we medicine a differentiated said potential we've that beta-thalassemia patients. to in cell
sites. Our EDIT-XXX of Phase is trial patients, and add X/X RUBY in active screening we study to continue
CMC study. us support all Our manufacturing is the required ready size the of with clinical group [ph] to for
by trial potential Health begin and an the of number We track also Canada, dosing will application received clinical expand we which of from on XXXX. the study remain to sites, approved end patient have
This We follow track we our Providing presented Additionally, June. potential highly our also in in induction Hematology for a remain enzyme robust shows beta-thalassemia by data beta-globin preclinical additional Association European on CasXXa hemoglobin support progenitor fetal the at of using cells. EDIT-XXX EDIT-XXX. the investigational drug new data locus that Congress and to benefits the in of erythroid editing application results the further at year-end. proprietary
high-level specificity, itself other target a view This occurring differentiates the highly approaches associated safety, editing longer disease which both will efficient sickle at occurred programs result in and by efficacy, naturally opposed to and and a no hemoglobin support and to with this fetal EDIT-XXX from these aim to for of short expression beta-thalassemia will specificity, life have and spans mutation through medicine we of anticipate demonstrating and mimics EDIT-XXX presented optimal persistence Importantly, patients. hereditary data lead and we the as robust cell with long-term safety other that and its to best-in-class approach sustained off hopefully detection a BCLXXA. target of fetal our editing. hemoglobin, treat that
patients, teams tirelessly to can promise we run get financial the working sooner the people's already through these to Michelle? forward. And lives. things to our deliver I'd sooner clinical like believe turn EDIT-XXX Michelle, medicines with I the XXX Our to and programs on to truly very briefly to operations been we move And over that, for have transform results. our that can
